Aim: Background: Voluminous of the anti-tumor drugs in practice known to yield adverse side effects for instance hepatotoxicity. Objective: This preliminary was carried out to ascertain the histological change after treatment with Sorafenib (SOR) before execution the B17 coadministration and detection of the histochemical change in Ascites Carcinoma mice model (EAC). Methods: In total 12 Swiss albino mice received intraperitoneal injections of Sorafenib (30 mg/ kg mouse) after tumor cells were injected, semi quantifiable scoring of the architectural disparities validated by histopathological inspection of mice tissues. Results: Upsurge of Liver enzymes, Kidney functions and significant reduction after SOR treatment of Hb, RBCs, and Platelets. Membrane integrity, separation of muscle fiber, Intrusion of inflammatory cells, Edematous intramuscular space were evaluated in addition, liver tissue revealed large focal area and diffuse pleomorphic darkly basophilic cells in the perivascular area around the dilated central vein (CV) besides the mild dilation of some blood sinusoids. Improvement in the histological pictures of hepatic tissues in comparison to EAC bearing positive control group were enhanced Conclusion: Sorafenib showed alterations in histological mice tissues, however improvements in biochemical parameters were noted; that's why the Coadministration of B17 will be applied to alleviate the side effects of Sorafenib on the next perspective study.

kidney toxicity rather than the undesirable effect of SOR in the tested parameters.

The transplantable tumor model of Ehrlich ascites tumor (EAC), which is a cancer simulation, is frequently used to study the antineoplastic effects of amygdalin (VB17). This study aims to find out how cardiac toxicity and oxidative stress triggered by EAC could be countered with VB17 in female mice. Twenty-five female mice were included and divided into 5 groups namely, the control group (Gp1), EAC (Gp2), VB17 control group (Gp3), EAC+VB17 (Gp4), EAC+VB17+SOR IP (Gp5). All groups underwent cardiac marker assessment in addition to oxidative stress marker MDA determination and the evaluation of the anti-oxidative stress marker of SOD. By comparison with the naïve control group, the EAC positive control group had a significantly higher level of Troponin, serum lactate dehydrogenase (LDH), CK-MB, CPK, and MDA content. On the other hand, the EAC group had significantly lower levels of cardiac SOD than the control group. Furthermore, better improvement in cardiac toxicity and oxidative stress was displayed by the cotreated (VB17+SOR) group 5 than by the (EAC + VB17) group 4. This led to the conclusion that VB17 conferred cardiac protective and antioxidant effects against EAC. This finding necessitates further research into the benefits of VB17 as adjuvant agents in the prevention and treatment of cardiac toxicity.